Probiotics show allergy, immune system benefits: Nestlé study


- Last updated on GMT

"The study was done during the actual grass pollen season, which makes the effect of the probiotic in our study even more impressive” - Singh et al.
"The study was done during the actual grass pollen season, which makes the effect of the probiotic in our study even more impressive” - Singh et al.

Related tags Allergy

A daily dose of Nestlé’s Bifidobacterium lactis NCC2818 probiotic strain may help manage allergic responses during pollen season, says a new study from the Nestlé Research Center.

Eight weeks of supplementation were associated with a decrease in levels of allergic and pro-inflammatory markers, compared with placebo, according to findings published in the European Journal of Clinical Nutrition​.

In addition, the probiotic supplement was found to affect the symptoms of hay fever (allergic rhinitis) with a significant reduction in nasal symptoms in the second month of the study, compared to placebo.

“These findings give two important pieces of information with respect to probiotics and their use for allergic rhinitis,”​ wrote the researchers. “First that for the beneficial effect of probiotics to manifest on the immune system and allergic symptoms, a continuous 8-week period of oral administration could be required to reach a possible beneficial outcome.

“It is also important to mention here that the study was done during the actual grass pollen season, which makes the effect of the probiotic in our study even more impressive.”

According to the FAO/WHO, probiotics are defined as "live microorganisms which when administered in adequate amounts confer a health benefit on the host"​.

Study details

Led by Anurag Singh, the Lausanne-based scientists recruited 20 people with seasonal allergic rhinitis to participate in their double-blinded, parallel, randomized placebo-controlled trial. Participants were randomly assigned to receive B. lactis​ NCC2818 or placebo for eight weeks.

Results showed that markers of allergic responses in the blood were lower in the probiotic group, including Th-2 cytokines, compared with the placebo group.

In addition, the researchers also looked at the activation levels of white blood cells that play a role in inflammatory reactions called basophils. Measuring the activation of basophils is a common tool to diagnose allergy. The new study revealed that activation of CD63 basophils was lower in the probiotic group after one month of supplementation, but there no differences between probiotic and placebo after eight weeks.

“The reduction in CD63 expression […] after 4 weeks of administration is reflective of the early impact the probiotic strain ​B. lactis NCC2818 has on the host immune system,” ​wrote Singh and co-workers.

“We wanted to conduct the trial during peak seasonal exposure to grass pollen (between May and August) as reflective to the real life situation and investigate if the probiotic strain ​B. lactis NCC2818 could impact the immune system and have an effect on AR symptoms,” ​they wrote.

“The fact that in this challenging clinical trial setting, probiotic administration could impact on immunological parameters, mainly Th-2 cytokine levels and basophil activation, and alleviate allergic symptoms compared with placebo treatment suggests that the strain ​B. lactis NCC2818 should be investigated further in large-scale trials.

“The probiotic field has generally struggled in translating promising in vitro and in vivo findings obtained in preclinical models into health benefits in human intervention clinical trials.

“We feel that the best way forward is to examine the candidate probiotic strains in proof of concept human clinical trials where the focus can be more on investigation of the different immune mechanisms via which a probiotic strain can impact on clinical symptoms, and then based on the findings engage in a subsequent large-scale trial with fewer outcomes and greater statistical power.”

Source: European Journal of Clinical Nutrition
Published online ahead of print, doi: 10.1038/ejcn.2012.197
“Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial”
Authors: A Singh, F Hacini-Rachinel, M L Gosoniu, T Bourdeau, S Holvoet, R Doucet-Ladeveze, M Beaumont, A Mercenier, S Nutten 

Probiotech and Microbiota 2013

Probiotech and Microbiota 2013 joins two conferences to join the dots between the lab and leading edge pre- and probiotic products in food, supplements and cosmetics.

Find out more here​.

Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

Related suppliers

Follow us


View more